Hence, we propose DRhQ as an effective therapeutic with possible clinical applications for patients with MS as well as those with other MIF/CD74 driven CNS conditions, including ischemic injury, traumatic brain injury, methamphetamine use disorder and Alzheimer’s disease. Here, MIF is linked to early-onset autosomal dominant Alzheimer disease.